Stay updated with breaking news from Lon Orph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH).  She says ORPH has firmly established its core pharma...
Open Orphan has 'firmly established its core pharma services offering' Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). She says ORPH has firmly established its core pharma services offering, underpinned by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already signed with the UK Government for COVID-19 vaccine challenge s...
Open Orphan: Unlocking the value of non-core assets ORPH has firmly established its core pharma services offering, underpinned by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already signed with the UK Government for COVID-19 vaccine challenge studies, pending finalisation of the characterisation study anticipated imminently. Furthermore, after extensive integ...